Dynamics of Isoagglutinin A and B After ABO-Incompatible HSCT

Overview

This study investigated the timing of disappearance and appearance of isoagglutinins A and B in patients undergoing ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT) over one year. It identified clinical factors influencing isoagglutinin kinetics and highlighted differences in the behavior of isoagglutinins A and B post-transplant.

Background

Allogeneic HSCT is a curative treatment for various hematological diseases, including malignant and non-malignant conditions. ABO incompatibility between donor and recipient can be major, minor, or bidirectional, potentially causing hemolysis and complications such as pure red cell aplasia. Despite these risks, ABO-incompatible HSCT outcomes are comparable to ABO-compatible transplants. Isoagglutinins, antibodies against ABO antigens, are key mediators of immunohematological complications, and their dynamics post-transplant may reflect engraftment status and relapse risk.

Data Highlights

The study included patients receiving ABO-incompatible HSCT at Geneva University Hospital from 2015 to 2019, with isoagglutinin A and B levels monitored every 3-4 days up to one year post-transplant. Data collected included recipient and donor blood types, conditioning regimen, immunosuppression, HLA mismatch, and clinical outcomes such as PRCA and relapse. Statistical analyses used interval survival methods to estimate cumulative incidence and median times for isoagglutinin disappearance and appearance.

Key Findings

• Isoagglutinin disappearance and appearance were analyzed independently of ABO incompatibility type over one year post-HSCT.
• Myeloablative conditioning regimens were associated with enhanced disappearance of isoagglutinins due to their cytotoxic effects.
• Isoagglutinin A and B showed different kinetics, with statistical comparison performed using proportional hazard models for interval survival data.
• Factors such as hematological disease type, use of anti-thymocyte globulin, HLA mismatch, and graft T-cell content influenced isoagglutinin dynamics.
• Reappearance of isoagglutinins after major ABO-incompatible HSCT may indicate hematological relapse.
• Monitoring isoagglutinin levels provides important immunohematological information to guide post-transplant management.

Clinical Implications

Regular monitoring of isoagglutinin A and B levels post-ABO-incompatible HSCT is crucial to detect early immunohematological complications and assess engraftment status. Conditioning intensity and immunosuppressive strategies should be considered when interpreting isoagglutinin kinetics. Awareness of isoagglutinin reappearance as a potential relapse marker can inform timely clinical interventions.

Conclusion

The study elucidates the temporal dynamics of isoagglutinin A and B following ABO-incompatible HSCT and identifies clinical factors influencing their disappearance and appearance. These findings support the integration of isoagglutinin monitoring into post-transplant care to optimize patient outcomes.

References

1. Geneva University Hospital Study 2015-2019 -- Dynamics of Isoagglutinin A and B Levels Following ABO-Incompatible HSCT